Deutsche Bank analyst James Shin maintains $Eli Lilly and Co (LLY.US)$ with a buy rating, and maintains the target price at $1,015.
According to TipRanks data, the analyst has a success rate of 36.4% and a total average return of -5.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Eli Lilly and Co (LLY.US)$'s main analysts recently are as follows:
Following Eli Lilly's Q3 earnings report, it is expected that there might be a more meticulous examination of Zepbound prescriptions and inventory levels. Nonetheless, the current belief is that the demand for GLP1 remains robust. Eli Lilly is considered to hold the top position for growth within the U.S. large-cap biopharmaceutical sector.
Eli Lilly experienced a fluctuating quarter for Mounjaro and Zepbound, attributed by analysts to inventory dynamics rather than supply or demand issues. Despite a stumble in the third quarter, the overall perspective on Eli Lilly remains favorable, although estimates for Mounjaro and Zepbound have been slightly reduced.
Following Eli Lilly's third-quarter report, there's an acknowledgement that the $1 billion shortfall in tirzepatide sales presents a significant challenge for the final quarter. This comes as inventory levels fluctuate and promotional efforts are delayed until later in the quarter.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
德意志銀行分析師James Shin維持$禮來 (LLY.US)$買入評級，維持目標價1,015美元。
根據TipRanks數據顯示，該分析師近一年總勝率為36.4%，總平均回報率為-5.5%。
此外，綜合報道，$禮來 (LLY.US)$近期主要分析師觀點如下：
在艾利莉莉發佈第三季度業績報告後，預計會對澤普邦處方和庫存水平進行更加細緻的審查。儘管如此，目前的信念是GLP1的需求仍然強勁。艾利莉莉被認爲在美國大市值生物製藥板塊中處於增長的頂尖位置。
艾利莉莉在Mounjaro和Zepbound上經歷了一個波動的季度，分析師認爲這是由庫存動態而不是供應或需求問題引起的。儘管第三季度出現了失誤，對艾利莉莉的整體看法仍然積極，儘管對Mounjaro和Zepbound的估值略有降低。
在艾利莉莉發佈第三季度報告後，人們承認tirzepatide銷售額10億美元的缺口對最後一個季度提出了重大挑戰。這是因爲庫存水平波動，促銷活動推遲至本季度後期。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
